| PMO Live 2015 Conference |
| 07/22 - 07/25/2015 |
| Seattle |
| USA |
| 0 | John A. Thompson Professor of Medicine, Member University of Washington, Fred Hutchinson Cancer Research Center |
| Sanjiv S. Agarwala MD Professor of Medicine Temple University School of Medicine Dr. Agarwala is Chief of Medical Oncology & Hematology and Director of the Melanoma and Immunology Program at St. Luke’s Cancer Center, Bethlehem, Pennsylvania. He is Professor of Medicine at Temple University School of Medicine, Philadelphia, Pennsylvania. Dr. Agarwala is nationally and internationally recognized as an expert in the research and treatment of melanoma. He graduated from the University of Bombay in India, and completed residencies and fellowships at the University of Bombay, Dunedin University in New Zealand, and the University of Pittsburgh in Pennsylvania. He has special interest and expertise in immunotherapy for cancer. He has been the principal investigator for several clinical trials involving immunotherapy and targeted therapy for melanoma and other malignancies. Dr. Agarwala has written more than 100 publications and book chapters on melanoma and other research areas. He is board certified in oncology, hematology, and internal medicine and is an active member of several professional and scientific societies, including the American Association for Cancer Research, American Society of Clinical Oncology, European Society for Medical Oncology, and Society for Melanoma Research.
| |
| Robert Andtbacka Associate Professor of Surgery Huntsman Cancer Institute Robert Andtbacka, MD, CM, FACS, FRCSC, is an Associate Professor in the Department of Surgery at the University of Utah, Huntsman Cancer Institute. Dr. Andtbacka received his medical degree from McGill University in Montreal, Canada, where he also completed a residency in general surgery. Before joining the University of Utah, he completed a 3-year fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center. He is board certified in general surgery by the American Board of Surgery and the Royal College of Surgeons of Canada. He is the Utah State Chair for the Commission on Cancer, and is a guideline committee member on the Melanoma Committee for the National Comprehensive Cancer Network, an organization that establishes national guidelines for the treatment of cancers. Dr. Andtbacka specializes in surgery for melanoma, skin cancer, soft tissue sarcomas, and cancers of the gastrointestinal tract. He is a National Institute of Health-funded researcher developing novel imaging methods to detect lymphatic spread of cancer cells and to determine tumor margins. His research interests also include injectable oncolytic immunotherapies in cutaneous malignancies, understanding resistance to targeted therapies in soft tissue sarcomas, including gastrointestinal stromal tumors (GIST), and novel therapeutics for solid tumors. He is a leader in using novel injectable intratumoral agents in melanoma and he is the principle investigator for several investigator-initiated, institutional, and multi-institutional clinical trials designed to improve diagnosis and treatments for cancer patients. | |
| Shailender Bhatia Assistant Professor University of Washington / Seattle Cancer Care Alliance Dr. Bhatia’s research efforts are mostly focused on clinical/translational research in skin cancers (especially Melanoma and Merkel cell carcinoma) and kidney cancer. He is especially interested in immune-based therapies. | |
| 0 | David G. Brodland MD Assistant Professor, Dermatology University of Pittsburgh |
| 0 | Jaehyuk Choi Assistant Professor in Dermatology Yale School of Medicine |
| Jorge E. Cortes MD Chair, CML and AML Sections D.B. Lane Cancer Research Dr. Cortes is deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, where he directs the CML and AML programs. He received his medical degree in 1986 from the Universidad Nacional Autonoma de Mexico, Mexico City, and has been at MD Anderson Cancer Center since 1991. Dr. Cortes, whose clinical interests focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemias, and myeloproliferative disorders, has authored more than 650 peer-reviewed medical publications. He has received numerous awards, including the Faculty Scholar Award from MD Anderson Cancer Center in 2003, the Annual Celgene Young Investigator Achievement Award for Clinical Research in Hematology in 2005, the Dr. John J. Kenny Award from the Leukemia & Lymphoma Society in 2006, the Service to Mankind Award from the Leukemia & Lymphoma Society in 2007, and the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2007. Dr. Cortes is Chief Editor of Current Hematological Malignancies Reports and Co–Chief Editor of Clinical Lymphoma, Myeloma & Leukemia. He also serves on the Editorial Board of the Journal of Clinical Oncology, Clinical Cancer Research, Leukemia & Lymphoma, and the American Journal of Hematology. Dr. Cortes is a member of the Board of Directors of the Leukemia & Lymphoma Society and President of the Latin American LeukemiaNet.
| |
| Madeleine Duvic Deputy Chairman of the Department of Dermatology The University of Texas MD Anderson Cancer Center Madeleine Duvic, M.D. is Professor of Internal Medicine and Dermatology and Deputy Chairman of the Department of Dermatology at The University of Texas, MD Anderson Cancer Center in Houston, Texas. She attended Rice University and Duke University Medical School, completing residencies in internal medicine and dermatology, and fellowship in molecular biology and geriatrics. She joined the faculty at Duke and University of Texas Medical School and Cancer Center where she established a translational molecular biology laboratory and a busy cutaneous lymphoma clinic (CTCL) focused on understanding the pathogenesis and developing new drugs for CTCL. Dr. Duvic is a member of the American Academy of Dermatology, served on the Board and committees, and directed AAD courses in molecular biology and lymphoma. She is an active member of the SID serving as Vice-President, Board Member, Chairman of the Program Committee, and former President of the southern section. She was elected to the ADA. She is a founder and board member of the United States Consortium for Cutaneous Lymphomas and a member of the scientific advisory committee of the Cutaneous Lymphoma Foundation and the National Alopecia Areata Foundation. She was Principal Investigator of the NIAMS and NAAF funded Alopecia Areata Registry and has been a reviewer for many NIH study sections. Dr. Duvic has been named as one of America's Top Doctors for over 10 consecutive years. She has authored over 425 peer-reviewed journal articles, three books, and has mentored numerous medical students, residents, fellows, and PhD students. Dr. Duvic has served as Principal Investigator in numerous clinical trials and translational research studies relating toT-cell lymphoma, melanoma, and skin cancer. At MD Anderson Cancer Center, she oversees clinical trials for patients with cutaneous T-cell lymphoma, developing and improving therapy for cutaneous T-cell lymphoma and educating other physicians. | |
| Axel Hauschild MD Professor of Dermatology University of Kiel Professor Axel Hauschild is Head of the Skin Cancer Working Group at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Germany. He is the past-President of the Dermatologic Cooperative Oncology Group (DeCOG) of Germany, Co-Chairman of the Global Melanoma Task Force (GMTF) and a board member of the European Association of Dermato-Oncology (EADO). He was the Congress President of the 8th World Congress on Melanoma in 2013 held in Hamburg, Germany. Professor Hauschild studied medicine at the Universities of Mainz, Lübeck, and Kiel, Germany, and held residencies at Kiel in the Departments of Cardiovascular Surgery and Dermatology. He became Senior Consultant in the Department of Dermatology in 1994 and Professor of Dermatology in 2004. His main interests are the diagnosis and treatment of skin cancer, dermatologic surgery, physician education and clinical trials, and he has been the principal investigator on more than 80 Phase I‒III clinical trials including studies on melanoma, cutaneous lymphomas and epithelial skin cancers (actinic keratosis, basal cell carcinoma). His scientific work was honoured with the German Skin Cancer Award (2003) and German Cancer Award (2011). Professor Hauschild has published over 250 articles in peer-reviewed journals, is a reviewer for 32 scientific journals and has been an invited presenter at over 600 national and international conferences.
| |
| Manuel Hidalgo MD, PhD Vicedirector for Translational Research Spanish National Cancer Research Centre Manuel Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialised in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programmes. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the pancreatic cancer research team - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilisation of personalised xenograft models for drug screening, biomarker development and personalised cancer treatment. He has published more than 220 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. In 2011, he was named Vice Director of Translational Research at CNIO charged with the mission to foster translational research at CNIO and with a broader implication of the Center in cancer care. | |
| Mohammed Kashani-Sabet Medical Director and Dermatologist Center for Melanoma Research and Treatment, Sutter Health CPMC Mohammed Kashani-Sabet, MD, is Medical Director of Cancer Programs at the California Pacific Medical Center. He also serves as director of the Center for Melanoma Research and Treatment and senior scientist at the CPMC Research Institute. Dr. Kashani-Sabet earned his medical degree from the State University ofNew York at Stony Brook, where he also completed an internship in internal medicine. He then completed a residency in dermatology at the University of California, San Francisco, as well as a post-doctoral fellowship in cutaneous oncology, and received training in both dermatology and medical oncology. Dr. Kashani-Sabet maintains clinical interests in melanoma and cutaneous lymphoma, and research interests in targeted therapy, ribozymes, siRNAs, tumor metastasis, prognostic factors, and tumor biomarkers. He has served as principal or co-investigator in several clinical trials of novel agents for melanoma and cutaneous lymphoma. He is a recipient of grant funding from the National Institutes of Health and the Department of Defense, and has served on several study sections for the National Cancer Institute. He serves on the editorial board of Journal ofTranslational Medicine, Journal of Skin Cancer, Cancer Gene Therapy, and Oncology Letters, and has served as an ad hoc reviewer for numerous journals, including The Lancet, Annals of Internal Medicine, and Journal of the National Cancer Institute. The author of over 1 00 peer-reviewed publications and 40 review articles/book chapters, as well as editor of2 textbooks, Dr. Kashani-Sabet has been an invited speaker at numerous regional, national, and international meetings and symposiums. | |
| Michael W. Kattan Chair, Quantitative Health Sciences, Professor of Medicine, Epidemiology and Biostatistics Cleveland Clinic Lerner College of Medicine, Case Western Reserve University Michael W. Kattan, Ph.D. is Chairman of the Department of Quantitative Health Sciences at The Cleveland Clinic and Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Kattan holds a Ph.D. in management information systems with a minor in statistitics. He also holds an MBA with concentration in quantitative sciences. Following his studies, he completed a postdoctoral program in medical informatics before joining the faculty at Baylor College of Medicine in Houston, Texas. With over 500 peer-reviewed publications, he is best known for his prediction models, called nomograms, in various cancers. He has received two patents for this work and serves on the several editorial boards including Cancer Investigation and Nature Clinical Practice Urology. Dr. Kattan has received several awards for his contributions to medical decision-making, most recently the John M. Eisenberg Award for Practical Applications of Medical Decision Making Research (SMDM) 2013. Dr. Kattan is interested in the development, validation, and use of prediction models. He has developed several such models in cancer and released them as freely available software, from www.nomograms.org and rcalc.ccf.org. Dr. Kattan is also interested in quality of life assessment to support medical decision making, such as utility assessment. Other interests include decision analysis and cost-effectiveness analysis. | |
| Michael Kolodziej National Medical Director Oncology Strategy Office of the Chief Medical Officer, Aetna Michael Kolodziej M.D. is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University Of Oklahoma School Of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He has published several manuscripts and given several presentations on oncology care delivery and reimbursement reform, use of evidence based treatment to enhance value, and personalized medicine. Since joining Aetna in January, 2013, he has been active in Aetna’s oncology delivery reform pilots, pharmacy policy, condition analysis, and genetics subcommittee. He is a Fellow of the American College of Physicians and is a member of the board of the Personalized Medicine Coalition. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (21) and Katherine (18). | |
| Mario E. Lacouture Dermatology Service Memorial Sloan-Kettering Cancer Center Dr. Lacouture did his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up. His research interests span the disciplines of dermatologic conditions in cancer patients, and those that arise as a consequence of chemotherapy and/or radiotherapy or stem cell transplants. Dr. Lacouture is a well-known lecturer in the US and abroad on dermatologic conditions as a result of cancer therapies. He founded a clinical program that encompasses patient care, education, and research on dermatologic care in cancer patients and survivors. He is currently Chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer and is on the advisory board of Cancer.Net and Bridges, the Newsletter for Cancer Survivors. In 2012, CancerCare named Dr Lacouture as Physician of the Year for his contributions to the education of people living with cancer. Dr Lacouture has published over 130 articles in peer-reviewed journals and is the author of Dr Lacouture’s Skin Care Guide for People Living With Cancer and Editor of the textbook Dermatologic Principles and Practice in Oncology. | |
| 0 | Karl D Lewis Associate Professor of Medicine University of Colorado Denver |
| 0 | Towia Libermann Associate Professor of Medicine, Director, BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center Division of Interdisciplinary Medicine and Biotechnology, Dana-Farber/Harvard Cancer Center |
| 0 | Roger Lo Associate Professor of Medicine/Dermatology & Molecular and Medical Pharmacology David Geffen School of Medicine at UCLA |
| 0 | Grant McArthur PhD Professor of Medicine, Director Skin and Melanoma Service, Co-head Cancer Therapeutics Program University of Melbourne, Peter MacCallum Cancer Centre |
| 0 | Funda Meric-Bernstam Department Chair, Department of Investigational Cancer Therapeutics, Medical Director The University of Texas MD Anderson Cancer Center |
| 0 | Steven A. Nelson Assistant Professor of Dermatology, Senior Associate Consultant College of Medicine, Mayo Clinic |
| Paul Nghiem MD, PhD Professor of Dermatology/Medicine and Pathology, Michael Piepkorn Endowed Chair in Dermatology Research University of Washington, Fred Hutchinson Cancer Research Center Dr. Paul Nghiem is the Michael Piepkorn Endowed Chair in Dermatology Research at UW and a Professor of Dermatology and Pathology at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle. He grew up in Olympia, Washington, and attended college at Harvard University. He then pursued MD and PhD degrees at Stanford University where he studied Cancer Biology and Immunology. He then completed: A medicine internship at Brigham and Women's Hospital in Boston. Dermatology residency at Massachusetts General Hospital in Boston. A Howard Hughes Post-Doctoral Fellowship with Stuart Schreiber in the Harvard Department of Chemistry and Chemical Biology. In 2003, he started his own lab at the Cutaneous Biology Research Center at Massachusetts General Hospital in Boston. In 2006, he and his wife moved 'home' to Seattle. He leads a multi-disciplinary team that follows a cohort of over 1000 patients with Merkel cell carcinoma. He has published over 80 papers that in aggregate have been cited over 2500 times. He currently has 5 grants from the NIH and other sources. | |
| 0 | Steven J O’Day Hematology/Oncology Director of Clinical Research, Director, Lost Angeles Skin Cancer Institute USC Keck School of Medicine, Adjunct Faculty, John Wayne Cancer Institute |
| Pierluigi Porcu MD Dr. Pierluigi Porcu, MD is currently an Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University Comprehensive Cancer Center. Dr. Porcu obtained his medical degree in 1987 and his Board certification in Medical Oncology in 1991 from the University of Torino, Italy. He then moved to Philadelphia to do cancer research work at Temple University and Thomas Jefferson University until June 1993. He completed a Residency in Internal Medicine in 1996 and a Fellowship in Hematology/Oncology in 1999 at Indiana University, Indianapolis, IN. He is currently the leader of the Cutaneous Lymphoma Program, and a member of the Viral Oncology Group of the OSU Comprehensive Cancer Center (OSUCCC), with a research focus in T/NK-cell, cutaneous T-cell lymphomas (CTCL) and EBV. He is a faculty inductee of the AOA. Dr. Porcu is a principal investigator (PI) for lymphoma clinical trials and is currently studying new treatments and biomarkers in T/NK-cell and EBV lymphoma. Since 2000 he has been a member of the NCCN NHL committee. Dr. Porcu has established one of the few multimodality cutaneous lymphoma clinics in the U.S, and has made the OSUCCC an internationally-recognized center for the study and treatment of cutaneous lymphoma. His research has been supported by an NIH/NCI K23 (2003-2008) and is now funded by the NCI (R21 CA164911), Pelotonia (Idea Award), and industry sponsors. Dr. Porcu is an international leader in cutaneous lymphoma. He was Secretary-Treasurer of the United States Cutaneous Lymphoma Consortium (USCLC) from 2009 to 2013 and is now its President (2014-2016). Since 2011 Dr. Porcu has been on the Board of Directors of the International Society of Cutaneous Lymphomas (ISCL). In 2009 Dr. Porcu was the co-Chair of the Cutaneous Lymphoma Summit, in New York City, the 1st integrated multidisciplinary meeting in cutaneous lymphoma. He is on the International Program Committee of the World Congress of Cutaneous Lymphoma and the World Cutaneous Malignancy Congress. From 2011 to 2013 he was on the Board of the Cutaneous Lymphoma Foundation (CLF), where he remains co-Chair of the Medical Affairs Committee. In this capacity, Dr. Porcu designed and helped launching The CLARIONS Research Award Program, the 2013 signature initiative of the CLF. Dr. Porcu is an enthusiastic and effective fundraiser for the OSUCCC. In 2009 he created Team CTCL, a cycling group that has raised ~$170,000 for Pelotonia. In addition, Dr. Porcu has partnered with the Cesidia Fund for Lymphoma Research (Columbus, OH), which hosts an annual fundraising dinner for T-cell and Cutaneous Lymphoma, which has brought nearly $150,000 in research funds for T/NK-cell lymphoma. Since 2012, Dr. Porcu has been a member of the ASH Development Committee and ASH Foundation. Finally, Dr. Porcu works extensively in the field of lymphoma education and mentoring, both at the academic level and in the community. He has taught undergraduate and graduate classes at OSU and was selected as the Cancer Signature Program liaison of the OSUCCC for the OSU Research Education Council Committee. For the past 3 years he has coordinated a post-graduate course on translational cancer research. He has mentored students and fellows in their application for research awards and funding. Dr. Porcu is very active in patient education forums, on behalf of patient advocacy organizations, such as the Cutaneous Lymphoma Foundation, CancerCare, and the Leukemia Lymphoma Society. | |
| 0 | Jerald Radich Member, Clinical Research Division, Associate Professor, Medical Oncology Division Fred Hutchinson Cancer Research Center, University of Washington School of Medicine |
| 0 | Merrick I Ross Director Translational Informatics Program, Boston University School of Medicine |
| 0 | Hemant K. Roy MD Professor of Medicine, Chief, Section of Gastroenterology Boston University School of Medicine, Boston Medical Center |
| Hope S. Rugo MD Professor of Medicine University of California, San Francisco Dr. Rugo is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care. She is an investigator in the Bay Area Specialized Program of Research Excellence at the UCSF Breast Cancer Center, the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is 1 of 3 recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of cancer-related topics. With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. In addition, she completed a 2-year postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care Physician of the Year Award in 2010.
| |
| Mark Sausen MD Vice President, Research and Development Personal Genome Diagnostics Dr. Sausen joined Personal Genome Diagnostics in 2013 and currently serves as the Vice-President of Research and Development. His prior research has focused on the development of novel tissue- and cell free DNA-based genomic approaches for the detection and analysis of cancer. Dr. Sausen has authored and co-authored several peer-reviewed articles in journals such as Science, Nature Genetics, and Science Translational Medicine on these topics. He received his B.A. from the University of Delaware in Biological Sciences and Ph.D. from the Johns Hopkins University in Cellular and Molecular Medicine where he was honored with the Hans J. Prochaska Young Investigator’s Award. | |
| Aleksander Sekulic Assistant Professor of Dermatology Mayo Clinic Dr. Sekulic received a M.D. degree from the University of Zagreb School of Medicine in Croatia. After receiving his M.D. degree, he attended Mayo Graduate School where he completed the Ph.D. degree in immunology. He further trained at Mayo Graduate School of Medicine where he completed a residency in dermatology. Dr. Sekulic’s clinical practice focuses on cutaneous oncology including malignant melanoma and other pigmented lesions, epidermal neoplasms, and cutaneous T-cell lymphoma. His research is centered on developing translational approaches for the study of genomics in skin diseases, identifying the genetics and molecular mechanisms of malignant melanoma, discovering the molecular diagnostics of pigmented lesions, and understanding the regulation of epidermal proliferation and differentiation as it relates to human skin disease. Dr. Sekulic has served as a teacher and mentor for numerous residents and students and is a recipient of the Excellence in Teaching Recognition Award at Mayo Medical School. He most recently was honored to receive the 2012 Gerstner Family Foundation Career Development Award in Individualized Medicine. He has given international, national, and regional presentations and has co-authored several articles, book chapters, abstracts, and letters which have been published in peer-reviewed journals including New England Journal of Medicine, The American Journal of Surgery, Journal of Cancer, Cancer Prevention Research, Oncologist, British Journal of Dermatology, and Mayo Clinic Proceedings. His research has been funded by the National Cancer Institute and other organizations. He holds professional memberships in societies such as the American Association for Cancer Research, American Association for the Advancement of Science, American Medical Association, Medical Dermatology Society, and the Minnesota Medical Association. | |
| 0 | Mark A. Socinski MD Professor of Medicine and Thoracic Surgery, Director, Lung Cancer Section University of Pittsburgh School of Medicine |
| 0 | Avi Spira Professor, Medicine, Pathology & Laboratory Medicine and Bioinformatics, Chef Computational Medicine |
| 0 | Manisha Thakuria Instructor in Dermatology Harvard Medical School |
| 0 | Roman Yelensky Senior Director, Biomarker and Companion Diagnostic Development Foundation Medicine |
